ReviewFrontiers in pharmacology2025
Combining exercise and nanoparticle-based therapies: a review of physiological synergies and pharmacological potential.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The convergence of nanotechnology and exercise science represents a novel pharmacological approach to enhance therapeutic efficacy, physiological resilience, and performance outcomes. Exercise is known to induce systemic adaptations-such as improved mitochondrial biogenesis, enhanced antioxidant defense, and neuroplasticity-while nanoparticles offer advanced pharmacokinetic profiles, including targeted delivery, controlled release, and increased bioavailability. Recent preclinical studies suggest that combining nanoparticle-based interventions with structured physical activity may produce synergistic effects that surpass the benefits of either strategy alone. This review critically examines the underlying molecular and cellular mechanisms involved in these interactions, with a focus on oxidative stress modulation, mitochondrial function, and neuroprotective pathways. Evidence from animal models highlights improvements in endurance, muscle regeneration, and cognitive preservation when bioactive compounds (e.g., resveratrol, curcumin, iron) are delivered via nanoparticle formulations. Notably, nano-encapsulation enhances pharmacodynamic outcomes compared to conventional delivery systems. Despite these promising findings, clinical translation remains limited, underscoring the urgent need for human trials to determine safety, optimal dosing, and sex-specific responses. Emerging directions include the integration of wearable biosensors for real-time monitoring, personalized exercise-nanotherapy protocols, and applications in neurodegenerative and metabolic disorders. Bridging nanomedicine and exercise pharmacology may unlock new pathways for precision health interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.